Study on the Construction and Anti-Tumor Effect of aPDL1/aMUC1 Double Antibody Modification of Doxorubicin Liposome

In recent years, the primary treatments for cancer have included chemotherapy, radiotherapy, and surgery. However, challenges such as poor prognosis, high recurrence rates, low survival rates, and diminished quality of life persist in cancer management. Recently, immunotherapy has emerged as a potent therapeutic approach for treating tumors. To this end, we developed antibodies for mucin 1 (MUC1) and programmed cell death ligand 1 (PD-L1) to functionalize liposomes and incorporate doxorubicin (DOX) (DOX-aMUC1/aPDL1-Lip). This formulation is designed to enhance its targeting capability and antitumor activity against cancer cells. The DOX-aMUC1/aPDL1-Lip formulation demonstrated significant antitumor effects both in vivo and in vitro, effectively inhibiting tumor cell growth. Utilizing antibodies against PD-L1 and MUC1 to modify liposomes represents a novel strategy for cancer treatment.